Search

Displaying results 1481 - 1490 of 2435 in total
  1. Drug

    SQ-109

    go.drugbank.com/drugs/DB05186
    Investigational

    SQ-109 is an orally active, small molecule antibiotic for treatment of pulmonary TB. Currently in Phase I clinical trials, SQ-109 could replace one or more drugs in the current first-line TB drug regimen, simplify therapy, and shorten th...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 Substrates
  2. Drug

    Bezisterim

    go.drugbank.com/drugs/DB05212
    Investigational

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  3. Drug

    Hepatitis B immune globulin

    go.drugbank.com/drugs/DB05276
    ApprovedInvestigational

    Long-term hepatitis B immune globulin (HBIG) has been shown to reduce hepatitis B virus (HBV) reinfection in patients transplanted for hepatitis B. Infection with hepatitis B may lead to hepatocellular carcinoma, a type of liver cancer. ...

    Products: HEPATITIS B IMMUNOGLOBULIN P BEHRING, HEPATITIS B IMMUNOGLOBULIN P BEHRING 1000 IU/5 ML IM KULLANIMA HAZIR ENJEKTÖRDE ENJEKSİYONLUK ÇÖZELTİ
  4. Drug

    Vandetanib

    go.drugbank.com/drugs/DB05294
    ApprovedInvestigational

    Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectabl...

    Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitors
  5. Drug

    Pimavanserin

    go.drugbank.com/drugs/DB05316
    ApprovedInvestigational

    Pimavanserin is an atypical antipsychotic indicated for the treatment of psychiatric disorders. Although the exact mechanism of action is unknown, it is thought that pimavanserin interacts with the serotonin receptors, particularly the 5...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  6. Drug

    Palovarotene

    go.drugbank.com/drugs/DB05467
    Approved

    Fibrodysplasia Ossificans Progressiva (FOP), with an estimated worldwide prevalence of one in 2 million individuals, is an exceptionally rare genetic disorder. FOP is caused by a gain-of-function mutation in the ACVR1/ALK2 gene which res...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 Inducers
  7. Drug

    Telaprevir

    go.drugbank.com/drugs/DB05521
    ApprovedWithdrawn

    Telaprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is...

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  8. Drug

    Apremilast

    go.drugbank.com/drugs/DB05676
    ApprovedInvestigational

    Apremilast, also known as Otezla, is a phosphodiesterase 4 (PDE4) inhibitor used to treat various types of symptoms resulting from certain inflammatory autoimmune diseases. It belongs to the same drug class as Roflumilast and Crisaborole...

    Categories: Cytochrome P-450 Substrates, P-glycoprotein substrates
  9. Drug

    Laromustine

    go.drugbank.com/drugs/DB05817
    Investigational

    VNP40101M is a novel alkylating agent that has been used in trials studying the treatment of Leukemia, Lymphoma, Lung Cancer, Small Intestine Cancer, and Myelodysplastic Syndromes, among others.

    Categories: Cytochrome P-450 CYP2B6 Inhibitors, Cytochrome P-450 Substrates
  10. Drug

    Sar9, Met (O2)11-Substance P

    go.drugbank.com/drugs/DB05875
    Investigational

    Sar9, Met (O2)11-Substance P is a neurokinin-1 receptor agonist. … It is an analog of the naturally occurring human neuropeptide Substance P, which can be found throughout the body, including in the airways of humans and many other species.

    Synonyms: 9-Sar-substance P sulfone, 9-Sar-11-met(O2)-substance P